ZBIO
Zenas BioPharma·NASDAQ
--
--(--)
--
--(--)
4.83 / 10
Netural
Fund flow data show a good score of 7.62/10, with positive Small, Medium, and Large inflows despite negative overall and Extra-large trends. Analyst sentiment is split: two analysts (Wedbush and Morgan Stanley) rate the stock Neutral or Buy with moderate confidence, but historical win rates are low (33.3% for Wedbush, 50% for Morgan Stanley). This blend of robust capital inflows and lukewarm analyst support maintains a neutral-to-slightly-positive tone for the stock.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-06
InstitutionMorgan Stanley
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for ZBIO?
- ZBIO holds a Bearish analyst rating, with 50% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.83/10 (Netural).
